Foix-Alajouanine Syndrome Medication
- Author: Cheryl Ann Palmer, MD; Chief Editor: Helmi L Lutsep, MD more...
With few exceptions, pharmacologic intervention is used only for symptomatic treatment of Foix-Alajouanine syndrome. Agents used in this therapy include the following:
Corticosteroids - Dexamethasone
Anticoagulants - Heparin
Antibiotics - Including amoxicillin and trimethoprim-sulfamethoxazole (TMP-SMZ); for bowel and bladder infections and terminal sepsis
Anti-inflammatory medications may improve neurologic disability during acute symptoms.
Dexamethasone is a synthetic adrenocortical steroid. During the acute phase of Foix-Alajouanine syndrome, intravenous (IV) dexamethasone may improve neurologic disability.
If angiographic evidence of thrombosis exists, anticoagulation with heparin may be indicated.
Heparin inhibits reactions that lead to blood clotting and the formation of fibrin clots (in vitro and in vivo). The drug is administered intravenously; oral administration is not effective. Adjust the dosage according to the patient's coagulation test results. The dosage is considered adequate when the activated partial thromboplastin time (aPTT) is 1.5-2 times normal. Continue heparin administration for at least 48 hours after the therapeutic value of aPTT has been reached.
Institute proper antibiotic therapy as indicated for bladder or bowel infections and for terminal sepsis, which frequently has a pulmonary etiology.
Amoxicillin is an analogue of ampicillin with broad-spectrum bactericidal activity against many gram-positive and gram-negative organisms.
TMP-SMZ is a synthetic, broad-spectrum antibacterial combination that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid, resulting in the inhibition of bacterial growth.
Krishnan P, Banerjee TK, Saha M. Congestive myelopathy (Foix-Alajouanine Syndrome) due to intradural arteriovenous fistula of the filum terminale fed by anterior spinal artery: Case report and review of literature. Ann Indian Acad Neurol. 2013 Jul. 16(3):432-6. [Medline]. [Full Text].
Mishra R, Kaw R. Foix-Alajouanine syndrome: an uncommon cause of myelopathy from an anatomic variant circulation. South Med J. 2005 May. 98(5):567-9. [Medline].
Foix CH, Alajouanine T. La myelite necrotique subaigue. Rev Neurol. 1926. 46:1-42.
Rodriguez FJ, Crum BA, Krauss WE, Scheithauer BW, Giannini C. Venous congestive myelopathy: a mimic of neoplasia. Mod Pathol. 2005 May. 18(5):710-8. [Medline].
Jellema K, Tijssen CC, van Gijn J. Spinal dural arteriovenous fistulas: a congestive myelopathy that initially mimics a peripheral nerve disorder. Brain. 2006 Dec. 129:3150-64. [Medline].
Iovtchev I, Hiller N, Ofran Y, Schwartz I, Cohen J, Rubin SA, et al. Late diagnosis of spinal dural arteriovenous fistulas resulting in severe lower-extremity weakness: a case series. Spine J. 2013 Oct 2. [Medline].
Sivakumar W, Zada G, Yashar P, Giannotta SL, Teitelbaum G, Larsen DW. Endovascular management of spinal dural arteriovenous fistulas. A review. Neurosurg Focus. 2009 May. 26(5):E15. [Medline].
Andres RH, Barth A, Guzman R, et al. Endovascular and surgical treatment of spinal dural arteriovenous fistulas. Neuroradiology. 2008 Oct. 50(10):869-76. [Medline].
Zhao LB, Shim JH, Lee DG, Suh DC. Two microcatheter technique for embolization of arteriovenous fistula with liquid embolic agent. Neurointervention. 2014 Feb. 9(1):32-8. [Medline].
Hessler C, Regelsberger J, Grzyska U, Illies T, Zeumer H, Westphal M. Therapeutic clues in spinal dural arteriovenous fistulas - a 30 year experience of 156 cases. Cen Eur Neurosurg. 2010 Feb. 71(1):8-12. [Medline].
Krause F. Chirurgie des Gehirns und Ruckenmarks nach eigenen Erfarungen. Berlin: Urban & Schwarzenberg; 1911.
Thorn, A. Spinale durale arteriovenöse Fisteln. Der Radiologe. November 2001. 41:955-960.